Federal Register / Vol. 79, No. 231 / Tuesday, December 2, 2014 / Notices 71433 

ESTIMATED ANNUALIZED BURDEN HOURS—Continued 

Type of respondent Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Adult Family Member ...................................... Family Core .................................................... 45,000 1 23/60 

Sample Adult ................................................... Adult Core ...................................................... 36,000 1 15/60 

Adult Family Member ...................................... Child Core ...................................................... 14,000 1 10/60 

Adult Family Member ...................................... Supplements .................................................. 45,000 1 20/60 

Adult Family Member ...................................... Followback ..................................................... 12,000 1 20/60 

Adult Family Member ...................................... Reinterview Survey ........................................ 5,000 1 5/60

Leroy A. Richardson, 

Chief, Information Collection Review Office, 

Office of Scientific Integrity, Office of the 

Associate Director for Science, Office of the 

Director, Centers for Disease Control and 

Prevention. 

[FR Doc. 2014–28233 Filed 12–1–14; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket No. CDC–2014–0012] 

Recommendations for Providers 

Counseling Male Patients and Parents 

Regarding Male Circumcision and the 

Prevention of HIV Infection, STIs, and 

Other Health Outcomes 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice with comment period. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), located 

within the Department of Health and 

Human Services (HHS), is seeking 

public comment on draft 

recommendations for health care 

providers who deliver information and 

counseling about elective male 

circumcision and the prevention of HIV 

and other adverse health outcomes to 

male patients and parents in the United 

States. The draft recommendations 

include information about the health 

benefits and risks of elective male 

circumcision performed by health care 

providers. 

DATES: Written comments must be 

received on or before January 16, 2015. 

ADDRESSES: You may submit comments 

identified by Docket Number CDC– 

2014–0012 by any of the following 

methods: 

• Federal eRulemaking Portal: http:// 

www.regulations.gov. Follow the 

instructions for submitting comments. 

• Mail: Division of HIV/AIDS 

Prevention, National Center for HIV/

AIDS, Viral Hepatitis, STD, and TB 

Prevention, Centers for Disease Control 

and Prevention, 1600 Clifton Road NE., 

Mailstop D–21, Atlanta, Georgia 30333. 

Attn: Male Circumcision 

Recommendations. 

Instructions: All submissions received 

must include the agency name and 

docket number or RIN. All relevant 

comments received will be posted 

without change to http://

regulations.gov, including any personal 

information provided. CDC will not 

consider or post any comments that 

contain vulgar or offensive language, 

threats, personal accusations, and/or 

statements intended to promote 

commercial products or services, or 

images. Additionally, CDC will not post 

any pictures that are submitted. For 

access to the docket to read the 

recommendations, background 

document, or comments received, go to 

http://www.regulations.gov. 

FOR FURTHER INFORMATION CONTACT: 

Division of HIV/AIDS, National Center 

for HIV/AIDS, Viral Hepatitis, STD, and 

TB Prevention, Centers for Disease 

Control and Prevention, 1600 Clifton 

Road NE., MS D–21, Atlanta, Georgia 

30329, phone: 404–639–5200. Email: 

circumcision@cdc.gov. 

SUPPLEMENTARY INFORMATION: These 

recommendations are intended to assist 

health care providers in the United 

States who are counseling men and 

parents of male infants, children and 

adolescents in decision making about 

male circumcision. Such decision 

making is made in the context of not 

only health considerations, but also 

other social, cultural, ethical, and 

religious factors. Although data have 

been accumulating about infant male 

circumcision for many years, clinical 

trials conducted between 2005–2010 

have demonstrated safety and 

significant efficacy of voluntary adult 

male circumcision performed by 

clinicians for reducing the risk of 

acquisition of human 

immunodeficiency virus (HIV) by a 

male during penile-vaginal sex 

(‘‘heterosexual sex’’). Three randomized 

clinical trials showed that adult male 

circumcision reduced HIV infection risk 

by 50–60% over time. These trials also 

found that adult circumcision reduced 

the risk of men acquiring two common 

sexually transmitted infections (STIs), 

herpes simplex virus type-2 (HSV–2) 

and types of human papilloma virus 

(HPV) that can cause penile and other 

anogenital cancers, by 30%. Since the 

release of these trial data, various 

organizations have updated their 

recommendations about adult male and 

infant male circumcision. 

In addition to obtaining public 

comment on the draft 

Recommendations, CDC considers this 

document to be important information 

as defined by the Office of Management 

and Budget’s (OMB) 2004 Information 

Quality Bulletin for Peer Review and, 

therefore, subject to peer review. CDC 

will share the summary of public 

comments with external experts who 

conduct a peer review of the evidence 

on this topic. Their review will include 

an evaluation of completeness, 

accuracy, interpretation, and 

generalizability of the evidence to the 

United States and whether the evidence 

is sufficient to support the draft 

counseling recommendations. 

After considering all public comment 

and the results of the peer review, CDC 

will publish a notice in the Federal 

Register announcing the final 

recommendations. 

Dated: November 19, 2014. 

Ron A. Otten, 

Acting Deputy Associate Director for Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2014–27814 Filed 11–28–14; 4:15 pm] 

BILLING CODE 4163–18–P 


rljohnson on DSK3VPTVN1PROD with NOTICES